What Clinicians Want to Know About the Current and Future Role of EZH1/2 Inhibitors in the Care of Patients with Lymphoma — Gilles Salles, MD, PhD

CME information and select publications

Featuring an interview with Dr Gilles Salles, including the following topics:

• Epigenetic modifications and the role of EZH2 in the pathobiology of follicular lymphoma (FL) (0:00)
• Natural history of FL and current treatment landscape in the first-line setting (5:20)
• Testing approaches for the detection of EZH2 mutations (14:37)
• Mechanism of action of the EZH inhibitors tazemetostat and valemetostat (18:31)
• Tazemetostat monotherapy as treatment for relapsed/refractory FL (20:58)
• Ongoing evaluation of novel treatment approaches with tazemetostat for FL and other lymphomas (25:31)
• Approved indications for tazemetostat for wild-type FL and FL with EZH2 mutations; sequencing of tazemetostat with bispecific antibodies and CAR T-cell therapy (34:07)
• Available clinical data with the novel dual EZH1/EZH2 inhibitor valemetostat (42:37)
• Personal experience with CAR T-cell therapy and perspectives on possible underlying reasons for the development of T-cell lymphoma in patients receiving this treatment (44:35)
• Management of FL in patients who experience relapse within 24 months of receiving treatment (POD24) (48:25)
• Myths or misperceptions associated with tazemetostat and other therapies approved in the relapsed FL setting (52:15)
• Perspectives on the future treatment landscape of FL (54:29)

CME information and select publications

Featuring an interview with Dr Stephen V Liu, including the following topics:

• Management of localized non-small cell lung cancer (NSCLC) (0:00)
• First-line treatment of advanced NSCLC (10:53)
• Targeted therapy for patients with NSCLC and actionable genomic alterations (30:24)
• Recent FDA approvals for NSCLC (37:49)
• Recent advances in small cell lung cancer (47:14)
• Lurbinectidin in combination with atezolizumab as front-line maintenance therapy for patients with early-stage SCLC (52:33)

CME information and select publications

Featuring perspectives from Dr Tanios Bekaii-Saab and Dr Philip A Philip, including the following topics:

• Introduction (0:00)
• Colorectal Cancer, Anal Cancer and Pancreatic Cancer — Dr Philip (1:56)
• Gastroesophageal Cancers, Hepatocellular Cancer and Biliary Tract Cancers — Dr Bekaii-Saab (41:48)

CME information and select publications

Featuring perspectives from Prof Francois-Clement Bidard and Dr Kevin Kalinsky, including the following topics:

• Introduction: Confronting Metastatic Breast Cancer (mBC) (0:00)
• Mechanisms of Resistance to Endocrine Therapy in HR-Positive mBC; Use of Oral Selective Estrogen Receptor Degraders (SERDs) — Dr Kalinsky (13:18)
• Ongoing Evaluation of Early Therapeutic Switching for HR-Positive mBC Harboring ESR1 Mutations — Prof Bidard (35:52)

CME information and select publications

Practical Perspectives: Optimizing the Role of BTK Inhibitors in the Management of Mantle Cell Lymphoma | Faculty Presentation — Michael Wang, MD

CME information and select publications.

Featuring perspectives from Dr Tycel Phillips and Dr Michael Wang, including the following topics:

• Introduction: Interface Between Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma (0:00)
• Key Datasets — Overview and First-Line Therapy (7:16)
• Faculty Case Presentations — Dr Phillips (27:03)
• Key Datasets — Relapsed/Refractory Disease (35:40)
• Faculty Case Presentations — Dr Wang (48:06)

CME information and select publications

Featuring a slide presentation and related discussion from Dr Erika Hamilton, including the following topics:

• Targeted therapies for ER-positive breast cancer (0:00)
• Clinical data with oral selective estrogen receptor degraders (2:13)
• Biological rationale for and mechanism of action of proteolysis-targeting chimeras (PROTACs) (7:07)
• Emerging data with PROTACs for ER-positive advanced breast cancer (9:17)
• Future directions with PROTACs for breast cancer (19:21)

CME information and select publications